

## Chimerix Inc

### COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 09-Jul-2013

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



**PLEASE NOTE:** the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Product Portfolio Summary..... 8

Product Portfolio Drugs..... 11

[Return to Table of Contents](#)

# Chimerix Inc

## COMPANY OVERVIEW

<b>Company Name</b>	Chimerix Inc
<b>Parent Company Name</b>	Chimerix Inc
<b>Website</b>	http://www.chimerix.com/
<b>Country</b>	US
<b>Number of Drugs in Active Development</b>	6
<b>Number of Inactive Drugs</b>	5
<b>Number of Patents as Owner</b>	17
<b>Number of Patents as Third Party</b>	1
<b>Number of Deals</b>	9
<b>Key Indications</b>	Cytomegalovirus infection,Adenovirus infection,BK virus infection,Influenza virus infection,Polyomavirus infection,DNA virus infection,Dengue virus infection,Epstein Barr virus infection,Hepatitis,Herpes simplex virus infection,Monkeypox virus infection,Mycobacterium tuberculosis infection,Plasmodium infection,Vaccinia virus infection,Variola virus infection
<b>Key Target-based Actions</b>	Hepatitis C virus NS5B polymerase inhibitor,Cytochrome P450 reductase inhibitor,P-Glycoprotein inhibitor,Acetaldehyde dehydrogenase stimulator,B-lymphocyte antigen CD20 stimulator,BCL2 gene inhibitor,Cytosine deaminase stimulator,Glutathione S-transferase stimulator,Homeobox protein NANOG stimulator,Integrin alpha-4/beta-1 antagonist,P-Glycoprotein 3 stimulator,POU domain 5 transcription factor 1 stimulator,SOX transcription factor 2 stimulator
<b>Key Technologies</b>	Small molecule therapeutic,Oral formulation,Parenteral formulation unspecified,Lipid,Prodrug,Nucleotide and derivatives,Oral sustained release formulation,Drug combination,Adult stem cell therapy,Antibody,Chemical purification,Condensational synthesis,Crystalline form,Dermatological formulation,Drug implant,Embryonic stem cell therapy,Hydrolytic synthesis,Oligonucleotide,Ophthalmic gel formulation,Pluripotent stem cell therapy,Salt synthesis

## COMPANY PROFILE

### SUMMARY

Chimerix Inc began operations in the third quarter of 2002, to commercialize the proprietary chemistry developed in the laboratory of Dr Karl Hostetler at the University of California San Diego and the Veterans Administration Hospital in San Diego, CA. The company uses its proprietary lipid conjugate technology to enhance the oral availability and delivery of antiviral drugs to improve dosing parameters, broaden therapeutic applications and decrease the risk of adverse reactions. Chimerix intends to develop drug candidates through proof-of-concept clinical trials before seeking to outlicense clinical candidates to pharmaceutical companies for late stage clinical trials, distribution, and marketing.

### LICENSING AGREEMENTS

In May 2006, Chimerix acquired Dr Leroy Townsend's chemical lead antiviral and oncology compound library from the University of Michigan. The company would add promising compounds to its technology platform, or license them to other pharmaceutical and biotechnology companies.

### EARLY R&D

By May 2010, the company was also investigating compounds for malaria and dengue fever.

By August 2009, the company was investigating hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza programs.

By May 2004, Chimerix was using its technology to create drug candidates for hepatitis C virus infection from known inhibitors of the viral polymerase.

[Return to Table of Contents](#)



## FINANCIAL

In June 2013, the company was to be added to the Russell 2000, Russell 3000 and Russell Global Indexes on June 28, 2013, as a part of the annual reconstitution of the Russell indexes.

In March 2013, Chimerix filed a Form S-1 with the US SEC for a proposed IPO of its common stock. In April 2013, the company priced the initial public offering of 7,320,000 common stock shares at \$14.00 each. At that time, the underwriters were granted a 30-day option to buy up to an additional 1,098,000 common stock shares to cover over-allotments, if any. The shares were traded under the symbol 'CMRX' on the NASDAQ Global market and the offering was expected to close on April 16, 2013. Later that month, the company completed an IPO 8,418,000 shares of its common stock. In May 2013, the company reported that the gross proceeds were \$117.9 million.

In February 2011, the company raised \$45 million from the closing of a series F financing.

In August 2009, Chimerix raised \$16.1 million from the closing of a series E financing.

In February 2007, Chimerix raised \$23.1 million from the private placement of series D preferred stock.

In November 2004, Chimerix raised \$11 million private placement of its series C preferred stock. The funds would augment a grant from the NIH for \$36.1 million awarded to Chimerix for the development of CMX-001 and would allow the company to accelerate its cytomegalovirus infection, multi-drug resistant HIV-1 infection and viral hepatitis programs.


In September 2003, Chimerix closed a \$3.1 million preferred stock private financing. The funds were to be used to support Chimerix's drug development programs for HIV and HCV, and to continue to support the company's R&D activities.

## PRODUCT PORTFOLIO SUMMARY

### DRUGS

#### Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

[Return to Table of Contents](#)

Indication	Active	Inactive	Total
Infectious disease	5	5	10
Respiratory disease	2	1	3
Gastrointestinal disease	1	2	3
Inflammatory disease	1	2	3

# Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	1
Discovery	5
Discontinued	1
No Development Reported	4

[Return to Table of Contents](#)



## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Funding	3	0	0	0	3
Drug - Asset Divestment	0	0	1	0	1
Drug - CRADA	1	0	0	0	1
Drug - Screening/Evaluation	1	0	0	0	1
Drug - Early Research/Development	1	0	0	0	1
Drug - Development/Commercialization License	1	0	1	0	2

## CLINICAL TRIALS

### Trials by Condition Studied

Condition Studied	Ongoing	All
Infectious disease	1	11
Inflammatory disease	0	1
Gastrointestinal disease	0	1

### Trials by Phase

Phase	Ongoing	All
Phase 3	1	2
Phase 2	0	3
Phase 1	0	5
Phase not specified	0	1

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)



## PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	0	1	1
Endocrine disease	2	1	3
Gastrointestinal disease	6	1	7
Genitourinary disease	3	0	3
Hematological disease	2	1	3
Degeneration	1	0	1
Andrology	2	0	2
Immune disorder	3	1	4
Musculoskeletal disease	1	0	1
Neoplasm	3	1	4
Ocular disease	1	0	1
Metabolic disorder	0	1	1
Neurological disease	1	1	2
Respiratory disease	3	0	3
Infectious disease	18	0	18
Inflammatory disease	6	0	6
Fatigue	1	0	1
Gynecology and obstetrics	1	0	1
Surgical procedure	0	1	1

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)



## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### CMX-001

<b>Drug Name</b>	CMX-001
<b>Key Synonyms</b>	
<b>Originator Company</b>	Chimerix Inc
<b>Active Companies</b>	Chimerix Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	DNA virus infection, Herpes simplex virus infection, Cytomegalovirus infection, Variola virus infection, BK virus infection, Epstein Barr virus infection, Polyomavirus infection, Adenovirus infection, Monkeypox virus infection, Vaccinia virus infection
<b>Target-based Actions</b>	
<b>Other Actions</b>	Viral replication inhibitor, Synergist
<b>Technologies</b>	Lipid, Oral formulation, Small molecule therapeutic
<b>Last Change Date</b>	04-Jun-2013

### antimalarial compounds, iThemba Pharmaceuticals/Medicines For Malaria Venture/Chimerix

<b>Drug Name</b>	antimalarial compounds, iThemba Pharmaceuticals/Medicines For Malaria Venture/Chimerix
<b>Key Synonyms</b>	
<b>Originator Company</b>	iThemba Pharmaceuticals Pty Ltd
<b>Active Companies</b>	iThemba Pharmaceuticals Pty Ltd, Chimerix Inc
<b>Inactive Companies</b>	Medicines for Malaria Venture
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Plasmodium infection
<b>Target-based Actions</b>	
<b>Other Actions</b>	Unspecified drug target, Antiparasitic
<b>Technologies</b>	Small molecule therapeutic
<b>Last Change Date</b>	08-Mar-2013

[Return to Table of Contents](#)



### nucleoside analogs (hepatitis C virus infection), Chimerix

<b>Drug Name</b>	nucleoside analogs (hepatitis C virus infection), Chimerix
<b>Key Synonyms</b>	
<b>Originator Company</b>	Chimerix Inc
<b>Active Companies</b>	Chimerix Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Hepatitis
<b>Target-based Actions</b>	Hepatitis C virus NS5B polymerase inhibitor
<b>Other Actions</b>	Antiviral
<b>Technologies</b>	Nucleotide and derivatives, Small molecule therapeutic
<b>Last Change Date</b>	07-Mar-2013

### influenza A and B virus targeting compounds, Chimerix

<b>Drug Name</b>	influenza A and B virus targeting compounds, Chimerix
<b>Key Synonyms</b>	
<b>Originator Company</b>	Chimerix Inc
<b>Active Companies</b>	Chimerix Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Influenza virus infection
<b>Target-based Actions</b>	
<b>Other Actions</b>	Unspecified drug target, Antiviral
<b>Technologies</b>	Small molecule therapeutic, Parenteral formulation unspecified
<b>Last Change Date</b>	12-Mar-2013

[Return to Table of Contents](#)

### dengue virus targeting compounds, Chimerix

<b>Drug Name</b>	dengue virus targeting compounds, Chimerix
<b>Key Synonyms</b>	
<b>Originator Company</b>	Chimerix Inc
<b>Active Companies</b>	Chimerix Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Dengue virus infection
<b>Target-based Actions</b>	
<b>Other Actions</b>	Unspecified drug target, Antiviral
<b>Technologies</b>	Small molecule therapeutic, Parenteral formulation unspecified
<b>Last Change Date</b>	12-Mar-2013

### Mycobacterium tuberculosis infection targeting compounds, Chimerix

<b>Drug Name</b>	Mycobacterium tuberculosis infection targeting compounds, Chimerix
<b>Key Synonyms</b>	
<b>Originator Company</b>	Chimerix Inc
<b>Active Companies</b>	Chimerix Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Mycobacterium tuberculosis infection
<b>Target-based Actions</b>	
<b>Other Actions</b>	Unspecified drug target, Antibacterial
<b>Technologies</b>	Small molecule therapeutic
<b>Last Change Date</b>	11-Mar-2013

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

